Vivo Capital, LLC
13F Reported Value
ⓘ$1.1B
Holdings
47
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Vivo Capital, LLC disclosed 47 positions worth $1.1B in its Form 13F-HR for Q2 2026, led by $TRVI (Trevi Therapeutics, Inc.) at 8.7% of the equity portfolio, followed by $PRAX and $ERAS. During the quarter the fund opened 8 new positions and exited 6 — including a new stake in $ACHV and a full exit from $TERN. The portfolio is most concentrated in Healthcare (98.3% of disclosed assets). All figures are sourced directly from Vivo Capital, LLC’s Form 13F-HR filing with the SEC under CIK 1674712.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$95.0M5,094,668 sh - $90.8M271,116 sh
- —
Quality
$75.6M4,127,412 sh - —
Quality
$58.4M1,682,097 sh - —
Quality
$55.3M414,899 sh - 17.6
Quality
$43.1M1,379,769 sh - —
Quality
$41.9M2,805,816 sh - —
Quality
$39.1M557,172 sh - —
Quality
$38.2M5,903,000 sh - —
Quality
$36.4M2,500,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Trevi Therapeutics, Inc.$TRVI | — | $95.0M | 5,094,668 |
 Praxis Precision Medicines, Inc.$PRAX | — | $90.8M | 271,116 |
 Erasca, Inc.$ERAS | — | $75.6M | 4,127,412 |
 ArriVent BioPharma, Inc.$AVBP | — | $58.4M | 1,682,097 |
 Abivax S.A.$ABVX | — | $55.3M | 414,899 |
 Tango Therapeutics, Inc.$TNGX | 17.6 | $43.1M | 1,379,769 |
 Corvus Pharmaceuticals, Inc.$CRVS | — | $41.9M | 2,805,816 |
 BRIGHT MINDS BIOSCIENCES INC.$DRUG | — | $39.1M | 557,172 |
 SINOVAC BIOTECH LTD$SVA | — | $38.2M | 5,903,000 |
 TENAX THERAPEUTICS, INC.$TENX | — | $36.4M | 2,500,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Vivo Capital, LLC's 47 positions.
Showing top 10 of 47 holdings.
Sector Allocation
Healthcare
$1.1B
Other
$18.1M
Full Holdings — Vivo Capital, LLC (Q2 2026)
All 47 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $TRVI | Trevi Therapeutics, Inc. | $95.0M | 8.7% | +0% | — |
| 2 | $PRAX | Praxis Precision Medicines, Inc. | $90.8M | 8.3% | -20% | — |
| 3 | $ERAS | Erasca, Inc. | $75.6M | 6.9% | -66% | — |
| 4 | $AVBP | ArriVent BioPharma, Inc. | $58.4M | 5.3% | +90% | — |
| 5 | $ABVX | Abivax S.A. | $55.3M | 5.0% | +73% | — |
| 6 | $TNGX | Tango Therapeutics, Inc. | $43.1M | 3.9% | -36% | 17.6 |
| 7 | $CRVS | Corvus Pharmaceuticals, Inc. | $41.9M | 3.8% | +0% | — |
| 8 | $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $39.1M | 3.6% | +0% | — |
| 9 | $SVA | SINOVAC BIOTECH LTD | $38.2M | 3.5% | +0% | — |
| 10 | $TENX | TENAX THERAPEUTICS, INC. | $36.4M | 3.3% | +1100% | — |
| 11 |  $ACRS | Aclaris Therapeutics, Inc. | $35.4M | 3.2% | +0% | 12 |
| 12 |  $DYN | Dyne Therapeutics, Inc. | $34.6M | 3.2% | +0% | — |
| 13 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $34.5M | 3.1% | +0% | 22.6 |
| 14 |  $ANRO | Alto Neuroscience, Inc. | $31.9M | 2.9% | +17% | — |
| 15 |  $DBVT | DBV Technologies S.A. | $30.3M | 2.8% | -31% | — |
| 16 |  $SABS | SAB Biotherapeutics, Inc. | $28.5M | 2.6% | -36% | — |
| 17 |  $MLTX | MoonLake Immunotherapeutics | $27.3M | 2.5% | +40% | — |
| 18 |  $LBRX | LB PHARMACEUTICALS INC | $26.0M | 2.4% | +0% | — |
| 19 |  $NERV | Minerva Neurosciences, Inc. | $24.0M | 2.2% | +0% | — |
| 20 |  $DSGN | Design Therapeutics, Inc. | $23.3M | 2.1% | +0% | — |
| 21 |  $ORIC | Oric Pharmaceuticals, Inc. | $20.0M | 1.8% | +0% | — |
| 22 |  $CAMP | Camp4 Therapeutics Corp | $18.6M | 1.7% | +0% | 25.3 |
| 23 | — | Faeth Therapeutics Inc - Common | $18.1M | 1.6% | +0% | — |
| 24 |  $ACHV | ACHIEVE LIFE SCIENCES, INC. | $18.0M | 1.6% | NEW | — |
| 25 |  $CMPX | Compass Therapeutics, Inc. | $17.0M | 1.6% | -19% | 28.1 |
| 26 |  $ANTX | AN2 Therapeutics, Inc. | $15.3M | 1.4% | +0% | — |
| 27 |  $EDIT | Editas Medicine, Inc. | $11.5M | 1.1% | NEW | 33.4 |
| 28 |  $GERN | GERON CORP | $11.1M | 1.0% | +0% | — |
| 29 |  $ODTX | Odyssey Therapeutics, Inc. | $10.8M | 1.0% | NEW | — |
| 30 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $8.9M | 0.8% | +0% | — |
| 31 |  $OKUR | OnKure Therapeutics, Inc. | $8.8M | 0.8% | +0% | — |
| 32 |  $OLMA | Olema Pharmaceuticals, Inc. | $8.4M | 0.8% | +0% | — |
| 33 |  $MNPR | Monopar Therapeutics | $8.4M | 0.8% | +0% | — |
| 34 |  $AURA | Aura Biosciences, Inc. | $8.3M | 0.8% | NEW | — |
| 35 |  $SRZN | Surrozen, Inc./DE | $6.7M | 0.6% | +0% | — |
| 36 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $6.6M | 0.6% | +0% | — |
| 37 |  $MSLE | Satellos Bioscience Inc. | $6.3M | 0.6% | NEW | — |
| 38 |  $AVTX | Avalo Therapeutics, Inc. | $5.1M | 0.5% | NEW | 11.7 |
| 39 |  $PEPG | PepGen Inc. | $4.2M | 0.4% | +0% | — |
| 40 |  $VALN | Valneva SE | $4.0M | 0.4% | NEW | 28.3 |
| 41 |  $SERA | SERA PROGNOSTICS, INC. | $3.0M | 0.3% | +0% | 3.1 |
| 42 |  $UNCY | Unicycive Therapeutics, Inc. | $2.6M | 0.2% | -69% | — |
| 43 |  $TIL | Instil Bio, Inc. | $2.3M | 0.2% | +0% | 30 |
| 44 |  $INM | InMed Pharmaceuticals Inc. | $1.2M | 0.1% | NEW | 13.1 |
| 45 |  $BOLT | Bolt Biotherapeutics, Inc. | $278,794 | 0.0% | +0% | — |
| 46 |  $KTTA | Pasithea Therapeutics Corp. | $239,904 | 0.0% | -78% | — |
| 47 |  $DTIL | PRECISION BIOSCIENCES INC | $36,746 | 0.0% | +0% | 10.6 |
New Positions (8)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Vivo Capital, LLC including:
Track Vivo Capital, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Vivo Capital, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Vivo Capital, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Vivo Capital, LLC (SEC CIK: 1674712), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Vivo Capital, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.